Experienced in Chronic T-Cell Leukemia (CTCL)

Dr. Shailesh R. Satpute

Hematology Oncology | Hematology | Oncology
Nsh Cancer Institute Professional Services G LLC
1100 Johnson Ferry Rd, Suite 600, 
Sandy Springs, GA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Experienced in Chronic T-Cell Leukemia (CTCL)
Nsh Cancer Institute Professional Services G LLC
1100 Johnson Ferry Rd, Suite 600, 
Sandy Springs, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shailesh Satpute is a Hematologist Oncology specialist and a Hematologist in Sandy Springs, Georgia. Dr. Satpute is rated as an Experienced provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Beta-Ketothiolase Deficiency, Iron Deficiency Anemia, Lung Cancer, Childhood Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Satpute is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Northside Hospital Forsyth
Northside Hospital Cherokee
Northside Hospital
Languages Spoken
English
Hindi
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

NSH CANCER INSTITUTE PROFESSIONAL SERVICES G LLC
1100 Johnson Ferry Rd, Suite 600, Sandy Springs, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Recruiting
Publish Date: October 15, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
View 4 Less Clinical Trials

1 Total Publications

Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care System.
Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regional Community Health Care System.
Journal: JTO clinical and research reports
Published: December 21, 2020
Similar Doctors
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Kevin H. Peacock
Hematology Oncology | Oncology | Hematology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Kevin H. Peacock
Hematology Oncology | Oncology | Hematology

North Atlanta Oncology Services LLC

2098 Teron Trce, Suite 400, 
Dacula, GA 
 (27.9 miles away)
678-722-3940
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kevin Peacock is a Hematologist Oncology specialist and an Oncologist in Dacula, Georgia. Dr. Peacock is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Paget Disease of the Breast, and Breast Cancer. Dr. Peacock is currently accepting new patients.

Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Maryjo J. Lechowicz
Hematology | Oncology | Transplant Surgery
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Maryjo J. Lechowicz
Hematology | Oncology | Transplant Surgery

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (8.1 miles away)
404-778-7525
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Maryjo Lechowicz is a Hematologist and an Oncologist in Atlanta, Georgia. Dr. Lechowicz is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). Her top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Gastric Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Lechowicz is currently accepting new patients.

Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Petros G. Nikolinakos
Hematology Oncology | Oncology | Hematology
Advanced in Chronic T-Cell Leukemia (CTCL)
Dr. Petros G. Nikolinakos
Hematology Oncology | Oncology | Hematology

University Cancer And Blood Center, LLC

3320 Old Jefferson Rd, Bldg 700, 
Athens, GA 
 (53.7 miles away)
706-353-2990
Languages Spoken:
English, French, Greek
See accepted insurances
Accepting New Patients
Offers Telehealth

Petros Nikolinakos is a Hematologist Oncology specialist and an Oncologist in Athens, Georgia. Dr. Nikolinakos is rated as a Distinguished provider by MediFind in the treatment of Chronic T-Cell Leukemia (CTCL). His top areas of expertise are Lung Cancer, Breast Cancer, Neuroendocrine Tumor, and Colorectal Cancer. Dr. Nikolinakos is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Satpute's expertise for a condition
ConditionClose
    View All 42 Advanced Conditions
    View All 172 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile